×
Metabolic Syndrome and the Risk of Coronary Heart Disease in 367 Patients Treated With Second-Generation Antipsychotic Drugs. PDF
$ 40.00
Metabolic Syndrome and the Risk of Coronary Heart Disease in 367 Patients Treated With Second-Generation Antipsychotic Drugs. PDF quantity
$ 40.00
×
Short-Term Efficacy and Safety of Desvenlafaxine in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder PDF
$ 40.00
Short-Term Efficacy and Safety of Desvenlafaxine in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder PDF quantity
$ 40.00
×
Longer Time to Antipsychotic Treatment Discontinuation for Any Cause Is Associated With Better Functional Outcomes for Patients With Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder PDF
$ 40.00
Longer Time to Antipsychotic Treatment Discontinuation for Any Cause Is Associated With Better Functional Outcomes for Patients With Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder PDF quantity
$ 40.00
×
Management of Acute Insomnia and Anxiety in a Patient With Myasthenia Gravis and Respiratory Failure PDF
$ 40.00
Management of Acute Insomnia and Anxiety in a Patient With Myasthenia Gravis and Respiratory Failure PDF quantity
$ 40.00
×
A Double-Blind, Multicenter, Parallel-Group Study of Paroxetine, Desipramine, or Placebo in Breast Cancer Patients (stages I, II, III, and IV) With Major Depression PDF
$ 40.00
A Double-Blind, Multicenter, Parallel-Group Study of Paroxetine, Desipramine, or Placebo in Breast Cancer Patients (stages I, II, III, and IV) With Major Depression PDF quantity
$ 40.00
Coupon: Apply coupon
Update cart
